← Back to Search

Procedure

Delayed Cord Clamping Techniques for Newborns with Congenital Heart Disease (CORD-CHD Trial)

N/A
Recruiting
Led By Madeline Rice, PhD
Research Sponsored by Carl Backes, MD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Fetal diagnosis of congenital heart disease (CHD) by prenatal ultrasound / echocardiography from local fetal ECHO, conducted between 18 - 36 weeks of gestation, rated as 3 - 6 on the Fetal Cardiovascular Disease Severity Score (FCDSS)
Be younger than 18 years old
Must not have
Planned fetal surgery
Major chromosomal defects identified prenatally (e.g., Trisomy 13, 18)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3-4 months after birth
Awards & highlights
No Placebo-Only Group

Summary

This trial will compare 2 delayed cord clamping techniques after birth for infants with CHD, to see which is more beneficial for both mother & baby.

Who is the study for?
This trial is for term-born infants with a prenatal diagnosis of congenital heart disease, rated moderate to severe. The mother must be at 37-41 weeks of gestation and give informed consent. Exclusions include surrogacy, certain maternal or fetal health conditions, major chromosomal defects, neuromuscular disorders, and participation in another study affecting cord clamping.
What is being tested?
The trial compares the effects of delaying umbilical cord clamping for ~120 seconds (DCC-120) versus ~30 seconds (DCC-30) on health and neuromotor outcomes in infants with CHD up to about two years old. It involves assessments at multiple stages postnatal and data collection from medical records.
What are the potential side effects?
While specific side effects are not detailed for this procedure-focused trial, potential risks may relate to the timing of cord clamping impacting infant blood volume and circulation immediately after birth.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My unborn baby has been diagnosed with a heart condition rated 3-6 on the FCDSS.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am scheduled for surgery on my unborn baby.
Select...
My unborn baby has been diagnosed with a major chromosomal defect.
Select...
I have a neuromuscular disorder like holoprosencephaly.
Select...
I need medication for my irregular heartbeat that can be given through the placenta.
Select...
I have a heart condition caused by my immune system.
Select...
I have a birth defect involving my diaphragm or abdomen.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3-4 months after birth
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3-4 months after birth for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Global Rank Score (Infant participant)
Secondary study objectives
Delivery Complications and Outcomes (Pregnant individual participant)
Impact of infant's congenital heart disease (Parents / Caregivers)
Neurodevelopmental Outcomes at 22-26 months (Infant participant)
+2 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Active Control
Group I: Delayed Cord Clamping at 30 Seconds (DCC-30)Active Control1 Intervention
The umbilical cord will be clamped between 1 - \<60 seconds following delivery, with a goal of around 30 seconds.
Group II: Delayed Cord Clamping at 120 Seconds (DCC-120)Active Control2 Interventions
The umbilical cord will be clamped at 60 - 180- seconds following delivery, with a goal of around 120 seconds. In the DCC-120 group, if there is concern for pregnant individual or baby and their doctor is not able to wait until at least 60 seconds, the doctor may do cord milking, which is four gentle squeezes of the umbilical cord pushing blood from the placenta to baby.

Find a Location

Who is running the clinical trial?

Duke Children's Hospital & Health CenterUNKNOWN
National Heart, Lung, and Blood Institute (NHLBI)NIH
3,943 Previous Clinical Trials
47,797,443 Total Patients Enrolled
Children's Hospital of PhiladelphiaOTHER
731 Previous Clinical Trials
8,472,334 Total Patients Enrolled
University of BristolOTHER
111 Previous Clinical Trials
25,026,047 Total Patients Enrolled
Boston Children's HospitalOTHER
789 Previous Clinical Trials
5,582,447 Total Patients Enrolled
Université de MontréalOTHER
221 Previous Clinical Trials
103,695 Total Patients Enrolled
Emory UniversityOTHER
1,708 Previous Clinical Trials
2,606,998 Total Patients Enrolled
Carl Backes, MDLead Sponsor
Duke UniversityOTHER
2,462 Previous Clinical Trials
2,968,420 Total Patients Enrolled
The George Washington University Biostatistics CenterOTHER
26 Previous Clinical Trials
110,832 Total Patients Enrolled
~333 spots leftby Oct 2028